Loader

Pathways

PathWhiz ID Pathway Meta Data

PW132519

Pw132519 View Pathway
metabolic

Tivozanib Drug Metabolism

Homo sapiens
Tivozanib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Tivozanib passes through the liver and is then excreted from the body mainly through the kidney.

PW146453

Pw146453 View Pathway
drug action

Tivozanib Drug Metabolism Action Pathway

Homo sapiens

PW127597

Pw127597 View Pathway
drug action

Tixagevimab Action Pathway

Homo sapiens
Tixagevimab is an extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.Tixagevimab, in combination with cilgavimab, was issued an FDA emergency use authorization on December 9, 2021. The combination of drugs was packaged as EVUSHELD and was granted marketing authorization by the EMA on March 28, 2022, then it was approved in Canada later on April 14, 2022. Certain SAR-CoV-2 Omicron subvariants may be associated with resistence to EVUSHELD. SARS-CoV-2 enters host cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Cilgavimab inhibits S glycoprotein by blocking the interaction between it and the host ACE2 protein. This inhibits the binding and entry of the virion into the host cell. This prevents viral replication and propagation.

PW132482

Pw132482 View Pathway
metabolic

Tixocortol Drug Metabolism

Homo sapiens
Tixocortol is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Tixocortol passes through the liver and is then excreted from the body mainly through the kidney.

PW145971

Pw145971 View Pathway
drug action

Tixocortol Drug Metabolism Action Pathway

Homo sapiens

PW126665

Pw126665 View Pathway
drug action

Tizanidine

Homo sapiens
Tizanidine is an alpha-2 adrenergic agonist used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. Spasticity is an increase in muscle accompanied by uncontrolled, repetitive contractions of skeletal muscles which are involuntary. Activation of alpha-2 adrenergic receptors on the presynaptic spinal motor neurons lead to the activation of Gi signaling cascade. This inhibits adenylyl cyclase and inactivates protein kinase A, thus decreasing calcium ion entry into the cell. Calcium in the cell is responsible for triggering the release of excitatory neurotransmitters such as glutamate (and aspartate) into the synapse. Glutamate acts on AMPA and NMDA receptors on the post synaptic motor neurons. Activation of AMPA receptors causes the influx of sodium in the post synaptic neuron. Activation of NMDA receptors causes an influx of calcium into the post synaptic neuron. The influx of positive ions in the cytosol causing depolarization of the motor neurons which then transmits a signal to muscle, causing muscle contraction/excitation. With reduced calcium entry in the presynaptic neuron, glutamate release is inhibited and less NMDA and AMPA receptors are activated, preventing depolarization of motor neurons and decreasing muscle contractions and spasms. Common adverse effects of taking tizanidine include drowsiness, blurred vision, dry mouth, weakness, constipation, nervousness, dizziness, hallucinations, dyskinesia, rhinitis.

PW144809

Pw144809 View Pathway
drug action

Tizanidine Drug Metabolism Action Pathway

Homo sapiens

PW176148

Pw176148 View Pathway
metabolic

Tizanidine Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Tizanidine are predicted with biotransformer.

PW123840

Pw123840 View Pathway
signaling

TLR

Homo sapiens

PW123671

Pw123671 View Pathway
signaling

TLR2

Homo sapiens